Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months

Russell, Fiona, Balloch, Anne, Licciardi, Paul V., Carapetis, Jonathan R., Tikoduadua, Lisi, Waqatakirewa, Lepani, Cheung, Yin, Mulholland, E. Kim and Tang, Mimi (2011). Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine,29(27):4499-4506.

Document type: Journal Article

IRMA ID jsingletonxPUB6
Title Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
Author Russell, Fiona
Balloch, Anne
Licciardi, Paul V.
Carapetis, Jonathan R.
Tikoduadua, Lisi
Waqatakirewa, Lepani
Cheung, Yin
Mulholland, E. Kim
Tang, Mimi
Journal Name Vaccine
Publication Date 2011
Volume Number 29
Issue Number 27
ISSN 0264-410X   (check CDU catalogue  open catalogue search in new window)
Start Page 4499
End Page 4506
Total Pages 7
Place of Publication United Kingdom
Publisher Elsevier Ltd
HERDC Category C1 - Journal Article (DIISR)
Abstract AIM:
To evaluate whether the avidity of serotype-specific IgG to pneumococcal serotypes is enhanced by an increased number of doses of the 7-valent pneumococcal conjugate vaccine (PCV) in infancy or by a 12 month 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster, and/or subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months.

METHODS:

Fijian infants aged 6 weeks were recruited, stratified by ethnicity and randomized to 8 groups to receive 0, 1, 2, or 3 doses of PCV, with or without 23vPPS at 12 months. All children received mPPS at 17 months of age. Avidity of serotype-specific IgG for PCV serotypes in the first 12 months and for all 23vPPS serotypes thereafter was assessed by EIA after sodium thiocyanate elution.

RESULTS:

At one month post primary series, the 2 and 3 PCV dose groups demonstrated similar avidity, with the single dose group tending to have lower avidity. However, by age 9 months, the single dose group had similar avidity to the 2 and 3 PCV groups for most serotypes. The 23vPPS booster enhanced affinity maturation for most serotypes and this was most marked in those groups that received a single PCV dose. There was little further increase following the mPPS.

CONCLUSIONS:

By 9 months of age, similar avidity can be induced following one, 2 or 3 doses of PCV. A 23vPPS booster at 12 months enhanced affinity maturation with an increase in antibody avidity for most serotypes. Subsequent re-challenge with mPPS at 17 months did not further enhance the avidity of serotype-specific response in the 12 month 23vPPS groups.
Keywords Pneumococcal antibody avidity
Infant pneumococcal vaccination
DOI http://dx.doi.org/10.1016/j.vaccine.2011.04.038   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 28 Abstract Views  -  Detailed Statistics
Created: Fri, 17 Jan 2014, 01:03:46 CST